Health care merger and acquisition activity reached a significant level in 2022, even if not matching 2021’s record-breaking standard. This reflects the overall economy’s holding pattern in which resources are still being deployed strategically, but not at full throttle.
At the same time, prognosticators including Moody’s have predicted that dealmaking may remain high over the next 12 to 18 months. This is due to a combination of factors, including pharmaceutical companies seeking to restock their pipelines in the face of approaching patent cliffs and long-term pricing pressure, Foley & Lardner write. Many of last year’s deals were underscored by significant ties to artificial intelligence technologies, a trend likely to become more prevalent going forward. Read more.
